NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $283,000 | +12.7% | 4,645 | -9.8% | 0.23% | +7.5% |
Q2 2018 | $251,000 | -49.8% | 5,147 | +9.3% | 0.21% | -51.4% |
Q1 2018 | $500,000 | -12.6% | 4,709 | -50.9% | 0.44% | -7.4% |
Q4 2017 | $572,000 | +129.7% | 9,582 | -7.6% | 0.48% | +117.9% |
Q3 2017 | $249,000 | +20.9% | 10,367 | -1.8% | 0.22% | +19.1% |
Q2 2017 | $206,000 | -19.5% | 10,553 | -3.1% | 0.18% | -19.4% |
Q1 2017 | $256,000 | +36.2% | 10,890 | -28.9% | 0.23% | +34.3% |
Q4 2016 | $188,000 | -27.1% | 15,322 | +1.9% | 0.17% | -30.2% |
Q3 2016 | $258,000 | +19.4% | 15,043 | -0.7% | 0.24% | +14.2% |
Q2 2016 | $216,000 | +3.8% | 15,146 | +0.1% | 0.21% | +2.9% |
Q1 2016 | $208,000 | -25.2% | 15,136 | -8.3% | 0.21% | -18.6% |
Q4 2015 | $278,000 | +57.1% | 16,514 | +2.3% | 0.25% | +31.8% |
Q3 2015 | $177,000 | -9.7% | 16,139 | +2.8% | 0.19% | -0.5% |
Q2 2015 | $196,000 | +32.4% | 15,699 | +16.3% | 0.19% | +33.1% |
Q1 2015 | $148,000 | -24.5% | 13,500 | +7.0% | 0.14% | -23.3% |
Q4 2014 | $196,000 | – | 12,616 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
CM Management, LLC | 35,000 | $595,000 | 0.55% |
OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |